

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

MAJOR TRANSACTION – DISPOSAL OF APPROXIMATELY 8.11% OF THE ISSUED SHARE CAPITAL OF THE TARGET COMPANY: FURTHER DELAY IN DESPATCH OF CIRCULAR AND CHANGE OF LONG STOP DATE OF THE SHARE REPURCHASE AGREEMENT

FURTHER DELAY IN DESPATCH OF CIRCULAR

References are made to (i) the announcement of New Ray Medicine International Holding Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) dated 20 April 2021 (“**Announcement**”) in relation to the disposal of approximately 8.11% of the issued share capital of WinHealth International Company Limited (維健國際有限公司) by the Group (“**Disposal**”); and (ii) the announcements of the Company dated 21 May 2021 and 21 June 2021 and the announcement of the Company dated 16 July 2021 (“**July Delay Announcement**”) in relation to the delay in despatch of the Circular. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the aforesaid announcements.

As stated in the July Delay Announcement, the Circular containing, among other things, further information on the Disposal, the Share Repurchase Agreement and the transactions contemplated thereunder and other information as required under the Listing Rules together with a notice of the SGM and a form of proxy will be despatched to the Shareholders on or before 30 July 2021.

Since additional time is required for the Company to finalise certain information to be included in the Circular, it is expected that the despatch of the Circular will be further postponed to a date on or before 20 August 2021.

CHANGE OF LONG STOP DATE OF THE SHARE REPURCHASE AGREEMENT

The Board further announces that on 30 July 2021, the Vendor, a wholly-owned subsidiary of the Company, and the Purchaser entered into the supplemental agreement to the Share Repurchase Agreement, pursuant to which the Vendor and the Purchaser agreed to extend the Long Stop Date for the satisfaction of the conditions precedent from 16 August 2021 to 16 September 2021 (or such other date as the Vendor and the Purchaser may agree in writing).

Save for the extension of the Long Stop Date, all material terms of the Share Repurchase Agreement as disclosed in the Announcement remain unchanged.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 30 July 2021

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.

Note: Trading in the Shares has been suspended with effect from 9:00 a.m. on 6 October 2017 by the Stock Exchange as directed by the Securities and Futures Commission in accordance with its direction issued under Section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V, the Laws of Hong Kong). Trading in the Shares will remain suspended until further notice. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.